DARPins against a functional IgE epitope

Immunology Letters

Volumn 133, Issue 2, 2010, Pages 78-84

  Baumann, Michael J ^a,b   Eggel, Alexander ^a   Amstutz, Patrick ^b   Stadler, Beda M ^a   Vogel, Monique ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b MOLECULAR PARTNERS AG   (Switzerland)

Author keywords

Allergic diseases; Anti IgE; DARPins; Designed ankyrin repeat proteins; Functional epitope; Omalizumab

Indexed keywords

ANTIALLERGIC AGENT; DESIGNED ANKYRIN REPEAT PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; OMALIZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; IMMUNOGLOBULIN HEAVY CHAIN GENE; IN VITRO STUDY; INHIBITION KINETICS; LEUKEMIA CELL LINE; MAST CELL LEUKEMIA; MEDIATOR RELEASE; MOLECULAR INTERACTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; RAT;

ANIMALS; ANKYRIN REPEAT; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ASTHMA; CELL LINE, TUMOR; EPITOPES, B-LYMPHOCYTE; HUMANS; IMMUNOGLOBULIN CONSTANT REGIONS; IMMUNOGLOBULIN E; PROTEIN BINDING; PROTEIN ENGINEERING; RATS; RECOMBINANT FUSION PROTEINS; TRANSGENES;

EID: 77956996031     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.07.005     Document Type: Article

References (61)

1. Burrows B., Martinez F.D., Halonen M., Barbee R.A., Cline M.G. Association of asthma with serum IgE levels and skin-test reactivity to allergens. The New England Journal of Medicine 1989, 320:271-277.
2. Ishizaka K., Ishizaka T. Identification of gamma-E-antibodies as a carrier of reaginic activity. Journal of Immunology 1967, 99:1187-1198.
3. Ishizaka K., Ishizaka T. Biological function of gamma E antibodies and mechanisms of reaginic hypersensitivity. Clinical and Experimental Immunology 1970, 6:25-42.
4. Kobayashi Y., Kondo N., Shinoda S., Agata H., Fukutomi O., Orii T. Predictive values of cord blood IgE and cord blood lymphocyte responses to food antigens in allergic disorders during infancy. The Journal of Allergy and Clinical Immunology 1994, 94:907-916.
5. Corne J., Djukanovic R., Thomas L., Warner J., Botta L., Grandordy B., et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. The Journal of Clinical Investigation 1997, 99:879-887.
6. Fahy J.V., Fleming H.E., Wong H.H., Liu J.T., Su J.Q., Reimann J., et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. American Journal of Respiratory and Critical Care Medicine 1997, 155:1828-1834.
7. Stadler B.M., Stampfli M.R., Miescher S., Furukawa K., Vogel M. Biological activities of anti-IgE antibodies. International Archives of Allergy and Immunology 1993, 102:121-126.
8. Heusser C., Jardieu P. Therapeutic potential of anti-IgE antibodies. Current Opinion in Immunology 1997, 9:805-813.
9. Tarantini F., Baiardini I., Passalacqua G., Braido F., Canonica G.W. Asthma treatment: 'magic bullets which seek their own targets'. Allergy 2007, 62:605-610.
10. Helm B., Kebo D., Vercelli D., Glovsky M.M., Gould H., Ishizaka K., et al. Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human epsilon-chain fragment of 76 amino acids. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:9465-9469.
11. Helm B., Marsh P., Vercelli D., Padlan E., Gould H., Geha R. The mast cell binding site on human immunoglobulin E. Nature 1988, 331:180-183.
12. Garman S.C., Wurzburg B.A., Tarchevskaya S.S., Kinet J.P., Jardetzky T.S. Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha. Nature 2000, 406:259-266.
13. Chang T.W. The pharmacological basis of anti-IgE therapy. Nature Biotechnology 2000, 18:157-162.
14. Ishizaka T., Tomioka H., Ishizaka K. Degranulation of human basophil leukocytes by anti-gamma E antibody. Journal of Immunology 1971, 106:705-710.
15. Leung D.Y., Sampson H.A., Yunginger J.W., Burks A.W., Schneider L.C., Wortel C.H., et al. Effect of anti-IgE therapy in patients with peanut allergy. The New England Journal of Medicine 2003, 348:986-993.
16. Presta L.G., Lahr S.J., Shields R.L., Porter J.P., Gorman C.M., Fendly B.M., et al. Humanization of an antibody directed against IgE. Journal of Immunology 1993, 151:2623-2632.
17. MacGlashan D.W., Bochner B.S., Adelman D.C., Jardieu P.M., Togias A., McKenzie-White J., et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. Journal of Immunology 1997, 158:1438-1445.
18. Adelroth E., Rak S., Haahtela T., Aasand G., Rosenhall L., Zetterstrom O., et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. The Journal of Allergy and Clinical Immunology 2000, 106:253-259.
19. Busse W.W., Massanari M., Kianifard F., Geba G.P. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. Current Medical Research and Opinion 2007, 23:2379-2386.
20. Casale T.B., Condemi J., LaForce C., Nayak A., Rowe M., Watrous M., et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001, 286:2956-2967.
21. Milgrom H., Fick R.B., Su J.Q., Reimann J.D., Bush R.K., Watrous M.L., et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 study group. The New England Journal of Medicine 1999, 341:1966-1973.
22. Molimard M., de Blay F., Didier A., Le Gros V. Effectiveness of omalizumab (Xolair((R))) in the first patients treated in real-life practice in France. Respiratory Medicine 2007.
23. Johansson S.G., Oman H., Nopp A., Pettersson S. The importance of IgE antibody levels in anti-IgE treatment. Allergy 2006, 61:1216-1219.
24. Oba Y., Salzman G.A. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. The Journal of Allergy and Clinical Immunology 2004, 114:265-269.
25. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nature Biotechnology 2005, 23:1126-1136.
26. Binz H.K., Amstutz P., Pluckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nature Biotechnology 2005, 23:1257-1268.
27. Binz H.K., Stumpp M.T., Forrer P., Amstutz P., Pluckthun A. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. Journal of Molecular Biology 2003, 332:489-503.
28. Eggel A., Baumann M.J., Amstutz P., Stadler B.M., Vogel M. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. Journal of Molecular Biology 2009, 393(3):598-607.
29. Amstutz P., Koch H., Binz H.K., Deuber S.A., Pluckthun A. Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries. Protein Engineering, Design and Selection 2006, 19:219-229.
30. Kawe M., Forrer P., Amstutz P., Pluckthun A. Isolation of intracellular proteinase inhibitors derived from designed ankyrin repeat proteins by genetic screening. The Journal of Biological Chemistry 2006, 281:40252-40263.
31. Sennhauser G., Amstutz P., Briand C., Storchenegger O., Grutter M.G. Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biology 2006, 5:e7.
32. Vogel M., Keller-Gautschi E., Baumann M.J., Amstutz P., Ruf C., Kricek F., et al. Designed ankyrin repeat proteins as anti-idiotypic binding molecules. Annals of the New York Academy of Science 2007, 109.
33. Zahnd C., Pecorari F., Straumann N., Wyler E., Pluckthun A. Selection and characterization of Her2 binding-designed ankyrin repeat proteins. The Journal of Biological Chemistry 2006, 281:35167-35175.
34. Zahnd C., Wyler E., Schwenk J.M., Steiner D., Lawrence M.C., McKern N.M., et al. A designed ankyrin repeat protein evolved to picomolar affinity to her2. Journal of Molecular Biology 2007, 369:1015-1028.
35. Baumann M.J., Stadler B.M., Vogel M. Potential applications of DARPins in diagnostics and therapeutics. Expert Opinion on Medical Diagnostics 2007, 1:409-421.
36. Stumpp M.T., Amstutz P. DARPins: a true alternative to antibodies. Current Opinion in Drug Discovery and Development 2007, 10:153-159.
37. Binz H.K., Amstutz P., Kohl A., Stumpp M.T., Briand C., Forrer P., et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nature Biotechnology 2004, 22:575-582.
38. Hanes J., Pluckthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:4937-4942.
39. Vogel M., Miescher S., Biaggi C., Stadler B.M. Human anti-IgE antibodies by repertoire cloning. European Journal of Immunology 1994, 24:1200-1207.
40. Zurcher A.W., Derer T., Lang A.B., Stadler B.M. Culture and IgE synthesis of nasal B cells. International Archives of Allergy and Immunology 1996, 111:77-82.
41. Zavazal V., Sach J., Rozprimova L., Brumelova V. An unusual case of IgE myeloma. Allergologia et Immunopathologia 1978, 6:423-426.
42. Neuberger M.S., Williams G.T., Mitchell E.B., Jouhal S.S., Flanagan J.G., Rabbitts T.H. A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 1985, 314:268-270.
43. Knutti-Müller J.M., Stadler B.M., Magnusson C.M., de Weck L. Human IgE synthesis in vitro. Detection with monoclonal antibodies. Allergy 1986, 41:457-467.
44. Nechansky A., Pursch E., Effenberger F., Kricek F. Characterization of monoclonal antibodies directed against the alpha-subunit of the human IgE high-affinity receptor. Hybridoma 1997, 16:441-446.
45. Zahnd C., Amstutz P., Pluckthun A. Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target. Nature Methods 2007, 4:269-279.
46. Wilson A.P., Pullar C.E., Camp A.M., Helm B.A. Human IgE mediates stimulus secretion coupling in rat basophilic leukemia cells transfected with the alpha chain of the human high-affinity receptor. European Journal of Immunology 1993, 23:240-244.
47. Alber G., Kent U.M., Metzger H. Functional comparison of Fc epsilon RI, Fc gamma RII, and Fc gamma RIII in mast cells. Journal of Immunology 1992, 149:2428-2436.
48. Bobrzynski T., Fux M., Vogel M., Stadler M.B., Stadler B.M., Miescher S.M. A high-affinity natural autoantibody from human cord blood defines a physiologically relevant epitope on the FcepsilonRIalpha. Journal of Immunology 2005, 175:6589-6596.
49. Roa M., Paumet F., Le Mao J., David B., Blank U. Involvement of the ras-like GTPase rab3d in RBL-2H3 mast cell exocytosis following stimulation via high affinity IgE receptors (Fc epsilonRI). Journal of Immunology 1997, 159:2815-2823.
50. Meng Y.G., Singh N., Wong W.L. Binding of cynomolgus monkey IgE to a humanized anti-human IgE antibody and human high affinity IgE receptor. Molecular Immunology 1996, 33:635-642.
51. Mirkina I., Schweighoffer T., Kricek F. Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab. Immunology Letters 2007, 109:120-128.
52. Sutton B.J., Beavil R.L., Beavil A.J. Inhibition of IgE-receptor interactions. British Medical Bulletin 2000, 56:1004-1018.
53. Davis F.M., Gossett L.A., Pinkston K.L., Liou R.S., Sun L.K., Kim Y.W., et al. Can anti-IgE be used to treat allergy?. Springer Seminars in Immunopathology 1993, 15:51-73.
54. Kolbinger F., Saldanha J., Hardman N., Bendig M.M. Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies. Protein Engineering 1993, 6:971-980.
55. Rudolf M.P., Zuercher A.W., Nechansky A., Ruf C., Vogel M., Miescher S.M., et al. Molecular basis for nonanaphylactogenicity of a monoclonal anti-IgE antibody. Journal of Immunology 2000, 165:813-819.
56. Wright J.D., Lim C. Prediction of an anti-IgE binding site on IgE. Protein Engineering 1998, 11:421-427.
57. Busse W.W. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. American Journal of Respiratory and Critical Care Medicine 2001, 164:S12-S17.
58. Hochhaus G., Brookman L., Fox H., Johnson C., Matthews J., Ren S., et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Current Medical Research and Opinion 2003, 19:491-498.
59. King C.L., Poindexter R.W., Ragunathan J., Fleisher T.A., Ottesen E.A., Nutman T.B. Frequency analysis of IgE-secreting B lymphocytes in persons with normal or elevated serum IgE levels. Journal of Immunology 1991, 146:1478-1483.
60. Harwood N.E., McDonnell J.M. The intrinsic flexibility of IgE and its role in binding FcepsilonRI. Biomedecine & Pharmacotherapie 2007, 61:61-67.
61. Price N.E., Price N.C., Kelly S.M., McDonnell J.M. The key role of protein flexibility in modulating IgE interactions. The Journal of Biological Chemistry 2005, 280:2324-2330.